Vericel reports FY2023 revenue $197.5M (+20% YoY); Q4 revenue $65.0M; FY2024 guidance $237-241M

Vericel Corp

2023-FY EPS reported -$0.07 revenue$197,516,000

Q4 net income $13.0M ($0.26 diluted EPS) vs $5.9M in Q4 2022, up 119%.
FY2023 net loss narrowed to $3.2M from $16.7M; adjusted EBITDA $33.9M (+40%).
MACI net revenue grew 22% to $56.7M in Q4; Burn Care revenue up 31% to $8.3M.
FY2024 total revenue guidance $237-241M; gross margin ~70%; adj. EBITDA margin ~20%.
Cash and investments $152.6M, zero debt; MACI arthroscopic delivery submission accepted by FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.